Literature DB >> 3888220

Endogenous release of hepoxilin A3 from isolated perifused pancreatic islets of Langerhans.

C R Pace-Asciak, J M Martin, E J Corey, W G Su.   

Abstract

Pancreatic islets of Langerhans were perifused with Krebs-bicarbonate solution containing glucose (5 and 10 mM). The perifusate was spiked with tetradeuterated hepoxilin A3 and was extracted and analysed by gas chromatography-mass spectrometry using NICI detection. Evidence is presented showing the presence of hepoxilin A3 as the hydrolysis product trioxilin A3. These results demonstrate for the first time that this pathway is active in intact cells; this finding, taken together with our previous evidence that hepoxilins possess insulin secretagogue properties further supports our hypothesis that these products could play a role as endogenous mediators of insulin release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888220     DOI: 10.1016/0006-291x(85)90137-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Novel eicosanoid pathways: the discovery of prostacyclin/6-keto prostaglandin F1alpha and the hepoxilins.

Authors:  Cecil R Pace-Asciak
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

Review 2.  The hepoxilins and some analogues: a review of their biology.

Authors:  Cecil R Pace-Asciak
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

3.  Hepoxilin A3 induces changes in cytosolic calcium, intracellular pH and membrane potential in human neutrophils.

Authors:  S Dho; S Grinstein; E J Corey; W G Su; C R Pace-Asciak
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

4.  A suggested shorthand nomenclature for the eicosanoids.

Authors:  D L Smith; A L Willis
Journal:  Lipids       Date:  1987-12       Impact factor: 1.880

5.  Hepoxilin A3-specific binding in human neutrophils.

Authors:  D Reynaud; P Demin; C R Pace-Asciak
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.